SCHEMBL15420133

SCHEMBL15420133

CCOC(=O)CNS(=O)(=O)Nc1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.47
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.38
NLRP3 Q96P20 1/20 0.38
HTT P42858 4/20 0.38
TDP1 Q9NUW8 1/20 0.38
GAA P10253 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.36
NPC1 O15118 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15419674 0.87 CA12 (0.41) ABCB1ALDH1A1L3MBTL1HTTGAA
SCHEMBL15419951 0.86 L3MBTL1 (0.53) ALDH1A1L3MBTL1HTTMEN1KMT2A
SCHEMBL9220154 0.75 ALDH1A1 (0.44) ABCB1ALDH1A1L3MBTL1TDP1GAA
SCHEMBL9832125 0.72 ABCB1 (0.47) ABCB1ALDH1A1L3MBTL1NLRP3HTT
SCHEMBL9829293 0.71 ABCB1 (0.51) ABCB1L3MBTL1NLRP3TDP1GAA
SCHEMBL13480885 0.70 GAA (0.48) ALDH1A1GAASMN1; SMN2CA12CA2
SCHEMBL3292956 0.70 GAA (0.48) ALDH1A1GAAKMT2ASMN1; SMN2CA12
SCHEMBL12959650 0.69 GAA (0.46) ALDH1A1GAASMN1; SMN2CA12CA2
SCHEMBL4031960 0.69 HPGD (0.58) ALDH1A1HTTGAAMEN1KMT2A
SCHEMBL9271365 0.68 HTT (0.50) ABCB1ALDH1A1L3MBTL1HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2740723-B1 SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KOREA RES INST CHEMICAL TECH (KR) 2017-05-10 EP disclosed
CN-104080766-B Sulphamide derivative having an adamantyl group and a pharmaceutically acceptable salt thereof 韩国化学研究院 2017-02-15 CN disclosed
US-9073906-B2 Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2015-07-07 US disclosed
EP-2740723-A2 SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Korea Research Institute of Chemical Technology (KR) 2014-06-11 EP disclosed
US-20140024636-A1 SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024636-A1 SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT HSD11B1, HSD11B2, HSD3B1 ABCB1 1003/4885ALDH1A1 46/4885L3MBTL1 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.